As part of its commitment to transparency and ToV reporting in line with the principles of EFPIA Code of Practice and various country Disclosure Codes and legal requirements for transparency, Norgine discloses reportable engagements with and ToV made to relevant healthcare stakeholders such as Healthcare Professionals (HCP), Healthcare Organisations (HCO), Patient Organisations (POrg) or other external individuals or legal entities that are subject to transparency reporting.
As mandated by the local legal regulations and Code(s) of Practice, and explained through methodology notes where applicable, countries disclose, as a minimum, ToV covering financial and/or non-financial support to:
Please click on the relevant country flag icon to view the information related to those reportable ToV over the last 3 years, directly or indirectly. The lack of availability of a country flag indicates that Norgine has not had any reportable ToV in the last 3 years, or is not mandated to disclose such information.
NB: In August 2025, Norgine acquired Theravia, an international pharmaceutical company specialising in therapies for patients with rare and debilitating conditions, and information about ToVs made by Theravia that year are visible under the relevant country flags below.
Norgine Pty Ltd is a member company of Medicines Australia and fully complies with the Medicines Australia Code of Conduct reporting requirements on payments to healthcare professionals (HCPs), Patient Organisations, Third Party Meetings Sponsorships and Grants and Donations (these reports may include payments to New Zealand HCPs or HCOs)
Click here for Norgine’s reports for up to 3 years
Payments to Healthcare Professionals – Medicines Australia
Third Party Meetings Sponsorships and Grants and Donations to Healthcare Organisations
Working with Patient Organisations (POrg)
Transfers of value: 2025, no ToV to publish for 2024, 2023
Methodology note: 2025, n/a for 2024, 2023
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Norgine is working towards full compliance with Pharmig VHC requirements to report payments and transfers of value to healthcare professionals and healthcare organisations. Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same. Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.
Working with Patient Organisations (POrg)
Norgine’s transfers of value to patient organizations in the three most recent reference years are publicly available together with the Methodology Notes on https://www.betransparent.be/en/. The transfers of value are published in line with the Belgian Law of 18 December 2016 containing various provisions relating to health, Title 3, Chapter 1 (Sunshine Act) and the Royal Decree of 14 June 2017 implementing the Sunshine Act.
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Norgine’s transfers of value to healthcare professionals and healthcare organizations in the three most recent reference years are publicly available together with the Methodology Notes on https://www.betransparent.be/en/. The transfers of value are published in line with the Belgian Law of 18 December 2016 containing various provisions relating to health, Title 3, Chapter 1 (Sunshine Act) and the Royal Decree of 14 June 2017 implementing the Sunshine Act.
Working with Patient Organisations (POrg)
Transfers of value: no ToV to publish for 2025, 2024, 2023
Methodology note: n/a
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Norgine is working towards full compliance with EFPIA requirements to report relevant transfers of value to healthcare professionals and healthcare organisations, even in territories where it has not got a physical presence.
Please click on the following links to consult the latest transfers of value in Czech Republic as well as the methodology notes providing further insight
Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology notes.
Transfers of value: 2025, no ToV to publish for 2024 or 2023
Methodology note: 2025, n/a for 2024 or 2023
Working with Patient Organisations (POrg)
Transfers of value: 2025, no ToV to publish for 2024 and 2023
Methodology note: 2025, n/a for 2024 and 2023
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Norgine is working towards full compliance with Pharma Industry Denmark (LIF) and EFPIA requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.
Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.
Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.
Working with Patient Organisations (POrg)
Transfers of value: 2025, no ToV to publish for 2024 and 2023
Methodology note: 2025, n/a for 2024 and 2023
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Norgine is working towards full compliance with Pharma Industry Finland (PIF) and EFPIA requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.
Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.
Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.
Working with Healthcare Professionals (HCP), Healthcare Organisations (HCO) and Patient Organisations (POrg)
NORGINE Pharma renommé NORGINE SAS, 23 RUE FRANCOIS JACOB, 92500 RUEIL MALMAISON
Date de mise à jour : May 2026
Conformément à la loi n°2011-2012 du 29 décembre 2011 relative au renforcement de la sécurité sanitaire du médicament et des produits de santé, et à son décret d’application n°2013-414 du 21 mai 2013, NORGINE SAS doit rendre publiques les informations relatives aux avantages consentis (supérieurs ou égaux à 10€) et aux conventions ou contrats conclus avec les professionnels et organisations de santé.
Conformément au décret du 28 décembre 2016 et l’arrêté du 22 mars 2017, Norgine SAS doit publier les rémunérations perçues par l’ensemble des acteurs de santé concernés, et ce, dès le 1er octobre 2017.
La publication des données concernant les conventions et le montant des avantages a lieu sur le site internet public unique mis en place par le Ministère de la Santé: www.transparence.sante.gouv.fr
Concernant la publication des informations sur le site public, et conformément à la loi « Informatique et Libertés » du 6 janvier 1978 modifiée, les professionnels de santé disposent d’un droit d’accès et de rectification des données personnelles qui les concernent. Pour exercer ce droit, merci de nous contacter via la base de données publique Transparence – Santé: www.transparence.sante.gouv.fr
Norgine a fait l’acquisition de Theravia en août 2025. Les informations relatives aux avantages consentis (supérieurs ou égaux à 10€) et aux conventions ou contrats conclus par Theravia avec les professionnels et organisations de santé français sont accessibles sur le site internet public unique https://www.transparence.sante.gouv.fr
Working with Patient Organisations (POrg)
Transfers of value: no ToV to publish for 2025, 2024, 2023
Methodology note: n/a
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Norgine is working towards full compliance with AKG-Transparenzregel requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.
Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.
Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.
Working with Patient Organisations (POrg)
Transfers of value: no ToV to publish for 2025, 2024, 2023
Methodology note: n/a
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Norgine is working towards full compliance with EFPIA requirements to report relevant transfers of value to healthcare professionals and healthcare organisations, even in territories where it has not got a physical presence.
Please click on the following links to consult the latest transfers of value in Greece as well as the methodology notes providing further insight
Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology notes.
Transfers of value: 2025, no ToV to publish for 2024 or 2023
Methodology note: 2025, n/a for 2024 or 2023
Working with Patient Organisations (POrg)
Transfers of value: no ToV to publish for 2025 and 2024, 2023
Methodology note: n/a for 2025 and 2024, 2023
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Norgine’s consultancy payments to healthcare professionals, sponsorships to attend scientific meetings and congresses, and grants and donations to healthcare organisations in Ireland are made in line with the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice for the Pharmaceutical Industry.
The IPHA code also mentions Research and development ToV – Research and Development Transfers of Value in each reporting period shall be disclosed by each company on an aggregate basis. Costs related to events that are clearly related to activities covered in this section can be included in the aggregate amount under the “Research and Development Transfers of Value” category.
Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.
Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.
Working with Healthcare Professionals (HCP), Healthcare Organisations (HCO) and Patient Organisations (POrg)
Norgine is working towards full compliance with Farmindustria and national law requirements to report payments and transfers of value to healthcare professionals, healthcare organisations and patient organisations.
Please click on the following links to have a view of the recent transfers of value and our methodologies for collecting the same.
Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology notes.
Working with Healthcare Professionals (HCP), Healthcare Organisations (HCO) and Patient Organisations (POrg)
Norgine is working towards full compliance with Transparantieregister Zorg, CGR and EFPIA requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.
Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.
https://www.transparantieregister.nl/home (Dutch version)
https://www.transparantieregister.nl/home?lang=en-us (English version)
Methodology note: 2025, 2024, 2023
Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Medicines New Zealand Transparency Guidelines provide a framework for Medicines New Zealand’s Member Companies to publicly report transfers of value annually.
The Guidelines only apply to Member Companies operating within New Zealand and payments made to New Zealand Healthcare Professionals.
Norgine has a limited presence in New Zealand, and is not a member of Medicines New Zealand. If any transfers of value are made from Norgine Pty Ltd to New Zealand HCPs or HCOs, they would be included in our reports to Medicines Australia.
For New Zealand, Norgine Pty Ltd applies the same reporting requirements as for Australia, the data can be accessed by clicking on the Australian flag.
Working with Patient Organisations (POrg)
Transfers of value to POrgs/Donations: no ToV to publish for 2025, 2024, 2023
Methodology note: n/a
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Norgine is working towards full compliance with Pharmaceutical Industry in Norway (LMI) and EFPIA requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.
Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.
Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.
Working with Patient Organisations (POrg)
Transfers of value: no ToV to publish for 2025, 2024, 2023
Methodology note: n/a
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Norgine is working towards full compliance with EFPIA requirements to report relevant transfers of value to healthcare professionals and healthcare organisations, even in territories where it has not got a physical presence.
Please click on the following links to consult the latest transfers of value in Poland as well as the methodology notes providing further insight
Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology notes.
Transfers of value: 2025, no ToV to publish for 2024 or 2023
Methodology note: 2025, n/a for 2024 or 2023
Working with Healthcare Professionals (HCP), Healthcare Organisations (HCO) and Patient Organisations (POrg)
Com o aditamento e alterações dos n.ºs 5 e 6 do referido Artigo 159.º, as entidades abrangidas pelos mesmos devem proceder à comunicação, no prazo de 30 dias, de todo e qualquer tipo de patrocínio concedido ou recebido.
Com o objetivo de implementar as ferramentas necessárias ao cumprimento das obrigações previstas naqueles preceitos, foi desenvolvida a Plataforma, que permitirá o preenchimento do formulário/declaração previsto na lei.
As comunicações feitas neste âmbito são da exclusiva responsabilidade dos respetivos declarantes.
O INFARMED, I.P., disponibilizará publicamente, de modo imediato e automático, no seu site, uma listagem resultante destas comunicações:
https://placotrans.infarmed.pt/publico/listagempublica.aspx
With the addition and changes to paragraphs 5 and 6 of said Article 159, the entities covered by the same must notify, within 30 days, any and all types of sponsorship granted or received.
In order to implement the tools required to comply with the obligations set out in those provisions, the Platform was developed, which will allow the completion of the form/declaration required by law.
The communications made within this scope are the exclusive responsibility of the respective declarants.
INFARMED, I.P. will immediately and automatically make a list of these communications publicly available on its website:
Working with Healthcare Professionals (HCP), Healthcare Organisations (HCO) and Patient Organisations (POrg)
Nota de Transparencia NORGINE de ESPAÑA S.L.U
Norgine trabaja para cumplir plenamente con los requisitos de FARMAINDUSTRIA y EFPIA para informar sobre los pagos y la transferencia de valor a los profesionales y organizaciones sanitarias.
Por favor, haga clic en los enlaces para ver las recientes transferencias de valor y nuestra metodología de recogida de las mismas.
Si tiene alguna pregunta relacionada con las transferencias de valor notificadas, póngase en contacto con nosotros a través de los datos de contacto que figuran al final de nuestra nota metodológica.
…
Norgine is working forwards full compliance with FARMAINDUSTRIA and EFPIA requirements to report payments and transfer of value to healthcare professionals and healthcare organisations.
Please click on the following links to have a view of the recent transfer of value and our methodology for collecting the same.
Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.
Transferencias de valor / Transfers of value: 2025, 2024, 2023
Nota Metodológica / Methodology note: 2025, 2024, 2023
AVISO LEGAL
La publicación de estos datos responde a las obligaciones de transparencia derivadas del Código de Buenas Prácticas de la Industria Farmacéutica.
De la publicación de la información no se deriva una habilitación general para que quienes accedan al sitio web puedan llevar a cabo un tratamiento adicional de los datos de los profesionales, tales como su cruce con las informaciones publicadas en los sitios web de otros asociados.
Norgine de España S.L.U. ha adoptado medidas de seguridad para evitar la indexación de la información a través de motores de búsqueda.
…
The publication of this data is in accordance with the transparency obligations arising from the Code of Good Practice for the Pharmaceutical Industry.
The publication of the information does not give general authorisation to those accessing the website to carry out additional processing of the data of professionals, such as cross-referencing it with information published on the websites of other partners.
Norgine de España S.L.U. has adopted security measures to prevent the indexing of information by search engines.
Working with Patient Organisations (POrg)
Transfers of value: no ToV to publish for 2025, 2024, 2023
Methodology note: n/a
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Norgine is working towards full compliance with Läkemedelsindustriföreningen and EFPIA requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.
Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.
Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.
Working with Patient Organisations (POrg)
Transfers of value: no ToV to publish for 2025, 2024, 2023
Methodology note: n/a
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Norgine is working towards full compliance with Pharma-Kodex and Pharma-Kooperations-Kodex requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.
Any transfers of value made to HCPs or HCOs from Liechtenstein are disclosed together with the data from Switzerland.
Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same.
Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology notes.
Working with Patient Organisations (POrg)
Transfers of value: 2025, 2024, 2023
Methodology note: 2025, 2024, 2023
Working with Healthcare Professionals (HCP) and Healthcare Organisations (HCO)
Norgine’s consultancy payments to healthcare professionals, sponsorships to attend scientific meetings and congresses, and grants and donations to healthcare organisations in the UK are made in line with the Association of British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry.
Please click on the following link to view the same: www.disclosureuk.org.uk
Working with Members of the Public, including Patients & Journalists
The information provided will typically include the fees paid and any associated expenses, as well as the type of service that was provided, e.g. speaking at meetings, providing assistance with training, advising on the design of clinical trials, participating in market research with remuneration and/or travel, participating in advisory boards, writing articles or publications.
Transfers of value: 2025, 2024, 2023
Methodology note: 2025, 2024, no requirement in 2023
Collaborative Working with Organisations
Norgine may be involved in collaborative working projects which either enhances patient care or are for the benefit of patients, or alternatively benefits the Health Services (e.g. NHS in UK) and, as a minimum, maintains patient care.
There are no collaborative arrangements to be disclosed for 2025, 2024 or 2023.